Show simple item record

dc.contributor.authorEl-Deeb, Ibrahim Mustafa
dc.contributor.authorYoo, Kyung
dc.contributor.authorLee, So
dc.date.accessioned2017-05-03T15:59:04Z
dc.date.available2017-05-03T15:59:04Z
dc.date.issued2011
dc.date.modified2014-08-28T22:58:32Z
dc.identifier.issn01986325
dc.identifier.doi10.1002/med.20206
dc.identifier.urihttp://hdl.handle.net/10072/37836
dc.description.abstractROS kinase is one of the last two remaining orphan receptor tyrosine kinases with an as yet unidentified ligand. The normal functions of human ROS kinase in different body tissues have not been fully identified so far. However, the ectopic expression, as well as the production of variable mutant forms of ROS kinase has been reported in a number of cancers, such as glioblastoma multiforme, and non-small cell lung cancer, suggesting a role for ROS kinase in deriving such tumors. It is thought also that c-ROS gene may have a role in some cardiovascular diseases, and the fact that homozygous male mice targeted against c-ROS gene are healthy but infertile, has inspired researchers to think about ROS inhibition as a method for development of new male contraceptives. The recent discovery of new selective and potent inhibitors for ROS kinase, along with the development of new specific diagnostic methods for the detection of ROS fusion proteins, raises the importance of using these selective inhibitors for targeting ROS mutations as a new method for treatment of cancers harboring such genes. This review focuses on the ectopic expression of ROS and its fusion proteins in different cancer types and highlights the importance of targeting these proteins for treatment of substantial cancers. It describes also the recent advances in the field of ROS kinase inhibition, and the potential clinical applications of ROS kinase inhibitors.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent237410 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley Interscience
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom794
dc.relation.ispartofpageto818
dc.relation.ispartofissue5
dc.relation.ispartofjournalMedicinal Research Reviews
dc.relation.ispartofvolume31
dc.rights.retentionY
dc.subject.fieldofresearchPharmaceutical Sciences
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry
dc.subject.fieldofresearchBiochemistry and Cell Biology
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode111504
dc.subject.fieldofresearchcode0304
dc.subject.fieldofresearchcode0601
dc.subject.fieldofresearchcode1115
dc.titleROS Receptor Tyrosine Kinase: A New Potential Target for Anticancer Drugs
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2010 Wiley Periodicals, Inc. This is the pre-peer reviewed version of the following article: ROS Receptor Tyrosine Kinase: A New Potential Target for Anticancer Drugs, Medicinal Research Reviews, which has been published in final form at http://dx.doi.org/10.1002/med.20206.
gro.date.issued2011
gro.hasfulltextFull Text
gro.griffith.authorEl-Deeb, Ibrahim Mustafa


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record